



Curriculum Vitae

<Last update: '25.9.24.>

Personal Details

Name:	Moon Haeng Hur, M.D., Ph.D.
Address:	101, Daehak-ro, Jongno-gu, Seoul, Republic of Korea
E-mail:	mhhur722@gmail.com mhhur@snu.ac.kr

Education/Training

2014.02	B.S., Department of Electrical Engineering and Computer Science, Seoul National University
2018.02	M.D., College of Medicine, Seoul National University
2024.02.	Ph.D., College of Medicine, Seoul National University

License

Medical License	License No.: 129290	Date: 16-02-2018
-----------------	---------------------	------------------

Work Experiences

2018.03 - 2019.02	Internship, Seoul National University Hospital
2019.03 - 2022.02	Residency, Department of Internal Medicine, Seoul National University Hospital
2022.03 - 2023.07	Fellowship, Department of Gastroenterology, Seoul National University Hospital
2023.08 -	Clinical Assistant Professor, Department of Gastroenterology, Seoul National University Hospital

Publications



[1] **Hur MH**, Yip TC, Kim SU, Lee HW, Lee HA, Lee HC, Wong GL, Wong VW, Park JY, Ahn SH, Kim BK, Kim HY, Seo YS, Shin H, Park J, Ko Y, Park Y, Lee YB, Yu SJ, Lee SH, Kim YJ, Yoon JH, Lee JH. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B. *J Hepatol.* 2025 Feb;82(2):235-244.

[2] Shin H, **Hur MH**, Song BG, Park SY, Kim GA, Choi G, Nam JY, Kim MA, Park Y, Ko Y, Park J, Lee HA, Chung SW, Choi NR, Park MK, Lee YB, Sinn DH, Kim SU, Kim HY, Kim JM, Park SJ, Lee HC, Lee DH, Chung JW, Kim YJ, Yoon JH, Lee JH. AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B. *J Hepatol.* 2025 Jun;82(6):1080-1088
(Co-first author).

[3] **Hur MH**, Park MK, Yip TC, Chen CH, Lee HC, Choi WM, Kim SU, Lim YS, Park SY, Wong GL, Sinn DH, Jin YJ, Kim SE, Peng CY, Shin HP, Chen CY, Kim HY, Lee HA, Seo YS, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Jang MJ, Kim YJ, Yoon JH, Lee JH. Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study. *Am J Gastroenterol.* 2023 Nov 1;118(11):1963-1972.

[4] **Hur MH**, Lee DH, Lee JH, Kim MS, Park J, Shin H, Chung SW, Cho HJ, Park MK, Jang H, Lee YB, Yu SJ, Lee SH, Jung YJ, Kim YJ, Yoon JH. Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study. *Clin Mol Hepatol.* 2024 Jul;30(3):500-514.

[5] **Hur MH**, Song W, Cheon D, Chang Y, Cho YY, Lee YB, Yu SJ, Kim YJ, Yoon JH, Choi HJ, NamKoong C, Lee JH. Chemogenetic stimulation of the parasympathetic nervous system lowers hepatic lipid accumulation and inflammation in a nonalcoholic steatohepatitis mouse model. *Life Sci.* 2023 Feb 28:121533.

[6] **Hur MH**, Cho Y, Kim DY, Lee JS, Kim GM, Kim HC, Sinn DH, Hyun D, Lee HA, Seo YS, Lee IJ, Park JW, Kim YJ. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. *Clin Mol Hepatol.* 2023 Jul;29(3):763-778.

[7] Ko Y, Song BG, Shin H, Park Y, Park J, Park MK, Lee YB, Yu SJ, Sinn DH, Kim YJ, Yoon JH, Park SS, **Hur MH**, Lee JH. Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis. *Osteoporos Int.* 2025 Aug;36(8):1391-1403 **(Co-corresponding author).**



[8] Ko Y, **Hur MH**, Park Y, Park J, Shin H, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease. *Gut Liver*. 2025 Sep 15;19(5):758-769 (**Co-first author**).

[9] **Hur MH**, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. *Cancers (Basel)*. 2021 Nov 29;13(23):6009.

[10] Park MK, **Hur MH**, Moon HS, Shin H, Chung SW, Won S, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study. *Liver Int*. 2024 Mar;44(3):799-810 (**Co-first author**).

[11] Kim J, **Hur MH**, Kim SU, Kim JW, Sinn DH, Lee HW, Kim MY, Cheong JY, Jung YJ, Lee HA, Jin YJ, Yoon JS, Park SJ, Lee CH, Kim IH, Lee JS, Cho YY, Kim HJ, Park SY, Seo YS, Oh H, Jun DW, Kim MN, Chang Y, Jang JY, Hwang SY, Kim YJ. Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study. *Cancers (Basel)*. 2023 May 26;15(11):2936 (**Co-first author**).

[12] Park J, Chung SW, Lee YB, Shin H, **Hur MH**, Cho H, Park MK, Youk J, Lee JY, Lee JO, Yu SJ, Kim YJ, Yoon JH, Kim TM, Lee JH. Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma. *Clin Mol Hepatol*. 2023 Jul;29(3):794-809.

[13] Kim J, Kim JY, Lee JH, Sinn DH, **Hur MH**, Hong JH, Park MK, Cho HJ, Choi NR, Lee YB, Cho EJ, Yu SJ, Kim YJ, Paeng JC, Kim HC, Yi NJ, Lee KW, Suh KS, Hyun D, Kim JM, Yoon JH. Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection. *J Nucl Med*. 2022 Aug;63(8):1215-1222.

[14] Choi NR, Kim JY, Hong JH, **Hur MH**, Cho H, Park MK, Kim J, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. *BMC Gastroenterol*. 2022 Mar 25;22(1):135.



[15] Chung GE, Kim JY, Shin H, Hong JH, **Hur MH**, Cho H, Park MK, Choi NR, Kim J, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Lee JH. Correlation between Results of Semi-Quantitative and Quantitative Tests for Hepatitis B Virus Surface Antigen among Patients Achieving Viral Suppression with Antiviral Treatment. *Diagnostics (Basel)*. 2022 Jul 20;12(7):1757.

[16] Chung SW, Cho H, Shin H, Park J, Kim JY, Hong JH, **Hur MH**, Park MK, Lee YB, Yu SJ, Lee M, Kim YJ, Paeng JC, Yoon JH, Chung JW, Lee JH, Kim HC. Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients. *Front Oncol*. 2023 Feb 28;13:1081479.

[17] Chung SW, Moon HS, Shin H, Han H, Park S, Cho H, Park J, **Hur MH**, Park MK, Won SH, Lee YB, Cho EJ, Yu SJ, Kim DK, Yoon JH, Lee JH, Kim YJ. Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study. *Hepatology*. 2024 Mar 11. Epub ahead of print.

[18] Yoon JS, Hong JH, Park SY, Kim SU, Kim HY, Kim JY, **Hur MH**, Park MK, Lee YB, Lee HA, Kim GA, Sinn DH, Park SJ, Lee YJ, Kim YJ, Yoon JH, Lee JH. High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study. *Aliment Pharmacol Ther*. 2024 Apr;59(8):973-983.

[19] Shin H, Kim SU, Song BG, Park Y, Ko Y, Park J, **Hur MH**, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Sinn DH, Kim YJ. Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real-world multicenter cohort study. *Hepatol Res*. 2024 Jul;54(7):627-637.

[20] Park J, Lee YB, Ko Y, Park Y, Shin H, **Hur MH**, Park MK, Lee DW, Cho EJ, Lee KH, Lee JH, Yu SJ, Kim TY, Kim YJ, Kim TY, Yoon JH. Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis. *J Liver Cancer*. 2024 Mar;24(1):81-91.

[21] Shin H, Lee HS, Noh JY, Koh JY, Kim SY, Park J, Chung SW, **Hur MH**, Park MK, Lee YB, Kim YJ, Yoon JH, Ko JH, Peck KR, Song JY, Shin EC, Lee JH. COVID-19 Vaccination Alters NK Cell Dynamics and Transiently Reduces HBsAg Titers Among Patients With Chronic Hepatitis B. *Immune Netw*. 2023 Oct 17;23(5):e39.



[22] Shin H, Choi WM, Kim SU, Ko Y, Park Y, Park J, **Hur MH**, Park MK, Lee YB, Kim YJ, Yoon JH, Lee JH, Zoulim F. Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis. *JHEP Rep.* 2024 Apr 8;6(7):101089.

[23] Shin H, Lim GS, Yoon JW, Ko Y, Park Y, Park J, **Hur MH**, Park MK, Cho Y, Lee YB, Cho EJ, Kim BH, Lee JH, Yu SJ, Yoon JH, Kim YJ. Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B. *J Med Virol.* 2024 Jul;96(7):e29760.

[24] Park J, Chung GE, Chang Y, Kim SE, Sohn W, Ryu S, Ko Y, Park Y, **Hur MH**, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis. *Gut Liver.* 2025 Jan 15;19(1):126-135.

[25] Yang H, Kim SS, Kang SH, Kwon J, Kim DY, Kim E, Shin HP, Yu JI, Yoo JJ, Yoon EL, Lee S, Chon YE, Jung J, Cheon J, Choi W, Han SK, Han JE, **Hur MH**, Lee HW, Kim HJ. Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria. *J Liver Cancer.* 2025 Jul 7. Epub ahead of print.

[26] Kim SS, Yang H, Kwon J, Kim E, Yu JI, Jung J, Choi W, Han JE, **Hur MH**, Kim BH, Kim SH, Kim JH, Kim H, Park PJ, Shin HP, Yu SJ, Yoon KT, Yoon SM, Lee M, Cho JY, Choi IY, Kim DY, Lee JS, Kim MS, Kim KS. Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea. *J Liver Cancer.* 2025 Sep 2. Epub ahead of print.